Avalo Therapeutics (NASDAQ:AVTX) CFO Christopher Ryan Sullivan Sells 12,394 Shares of Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Sullivan sold 12,394 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total transaction of $202,394.02. Following the sale, the chief financial officer directly owned 39,900 shares in the company, valued at approximately $651,567. The trade was a 23.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Ryan Sullivan also recently made the following trade(s):

• On Thursday, September 10th, Christopher Sullivan sold 10,185 shares of Avalo Therapeutics stock. The stock was sold at an average price of $17.62, for a total transaction of $179,459.70.

Avalo Therapeutics Trading Down 0.7%

Shares of NASDAQ:AVTX opened at $16.57 on Friday. The company has a 50-day moving average price of $18.76 and a 200 day moving average price of $17.04. Avalo Therapeutics, Inc. has a 12 month low of $10.70 and a 12 month high of $24.27. The company has a market cap of $888.65 million, a price-to-earnings ratio of -3.79 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last released its earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.25). As a group, equities analysts forecast that Avalo Therapeutics, Inc. will post -2.69 EPS for the current year.

Analysts Set New Price Targets

AVTX has been the topic of several analyst reports. Guggenheim set a $48.00 price target on shares of Avalo Therapeutics and gave the company a “buy” rating in a report on Friday, August 7th. Wall Street Zen downgraded shares of Avalo Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Avalo Therapeutics in a research note on Wednesday. Leerink Partners initiated coverage on Avalo Therapeutics in a report on Monday, July 6th. They issued an “outperform” rating and a $38.00 price target on the stock. Finally, BTIG Research reiterated a “buy” rating and set a $58.00 target price on shares of Avalo Therapeutics in a research report on Tuesday, June 16th. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $45.10.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AVTX. Braidwell LP bought a new stake in Avalo Therapeutics during the 2nd quarter valued at $30,107,000. Affinity Asset Advisors LLC grew its position in shares of Avalo Therapeutics by 27.6% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after buying an additional 289,786 shares in the last quarter. Seven Fleet Capital Management LP grew its position in shares of Avalo Therapeutics by 34.3% during the 2nd quarter. Seven Fleet Capital Management LP now owns 770,765 shares of the company’s stock worth $14,244,000 after buying an additional 196,882 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Avalo Therapeutics by 3.5% during the first quarter. Bank of America Corp DE now owns 643,000 shares of the company’s stock valued at $9,600,000 after buying an additional 21,650 shares during the period. Finally, Squarepoint Ops LLC increased its stake in shares of Avalo Therapeutics by 624.9% during the second quarter. Squarepoint Ops LLC now owns 589,245 shares of the company’s stock valued at $10,889,000 after buying an additional 507,960 shares during the period. Institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research strategy centers on treatments intended to address conditions in which abnormal immune system activity contributes to disease progression.

Avalo’s lead product candidate is AVTX-009, an investigational fully human monoclonal antibody designed to inhibit interleukin-1 beta (IL-1β), a signaling protein involved in inflammation.